
Aspo's Board of Directors decided on the payment of the second dividend installment
Aspo Plc
Stock exchange release
November 1, 2023 at 11:30 a.m.
Aspo's Board of Directors decided on the payment of the second dividend installment
The Board of Directors of Aspo Plc has decided on the payment of the second dividend installment of EUR 0.23 per share, based on the authorization of the Annual Shareholders' Meeting on April 4, 2023. The dividend will be paid to shareholders who are registered in the shareholders' register maintained by Euroclear Finland Ltd on the record date November 3, 2023. The dividend payment date will be November 10, 2023. Following the dividend payment, Aspo will have distributed a total dividend of EUR 0.46 per share in 2023 according to the decision of the Annual Shareholders' Meeting.
Aspo Plc
Rolf Jansson
CEO
For further information, please contact:
Arto Meitsalo, CFO of Aspo Plc, +358 40 5511 422, arto.meitsalo@.com
DISTRIBUTION:
Nasdaq Helsinki
Key media
www.aspo.com
Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 18 different countries, and it employs a total of approximately 800 professionals.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ledende medarbejders transaktioner28.11.2023 14:58:15 CET | pressemeddelelse
Selskabsmeddelelse Nr. 7/2023 København, 28. november 2023 Ledende medarbejders transaktioner Bestyrelsen i Conferize A/S er i dag blevet bekendt med, at 7 investorer har købt 40,26 pct. af selskabets eksisterende aktier fra selskabets 2 hovedaktionærer til en samlet pris på ca. 0,8 mio. kr. – svarende til en pris på 0,01 kr. pr. aktie. Direktør Nicolai Bille Krogh har solgt aktier i Conferize A/S. NAVN:7DREAMS ApSÅRSAG:Nærtstående til Nicolai Bille Krogh, DirektørUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28.11.2023MARKED:Nasdaq First North Growth MarketANTAL STK:40.078.446SALGSSUM DKK:400.784,46 Herudover har Rothausen Development 2016 ApS ejet og kontrolleret af direktør i Suubz ApS, datterselskab i Conferize A/S, solgt aktier i Conferize A/S NAVN:Rothausen Development 2016 ApSÅRSAG:Nærtstående til Claus Andersen, Direktør i datterselskab Suubz ApSUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28
2024 Financial Calendar28.11.2023 14:56:32 CET | Press release
28 November 2023 News Release Pharma Equity Group 2024 Financial Calendar March 4Deadline for shareholder proposals - Annual General meeting March 20 Annual Report 2023 April 16Annual General Meeting May 16Interim Report – for the three-month period ended March 31, 2024 August 16Interim Report – for the six-month period ended June 30, 2024 November 15Interim Report – for the nine-month period ended September 30, 2024 Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: investor@pharmaequitygroup.com. About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthc
Finanskalender for 202428.11.2023 14:56:32 CET | pressemeddelelse
28. november 2023 Pressemeddelelse Pharma Equity Group Finanskalender for 2024 4. martsFrist for aktionærforslag - Ordinær generalforsamling 20. marts Årsrapport 2023 16. aprilOrdinær generalforsamling 16. majDelårsrapport – for den tremåneders periode, der sluttede 31. marts 2024 16. augustDelårsrapport – for halvåret, der sluttede 30. juni 2024 15. novemberDelårsrapport – for den ni måneders periode, der sluttede 30. september 2024 Kontaktperson – Investor Relations På selskabets hjemmeside www.pharmaequitygroup.com kan yderligere information og alle offentliggjorte meddelelser findes. Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Thomas Kaas Selsø, CEO, Telefon: +45 4022 2114 E-mail: investor@pharmaequitygroup.com. Om Pharma Equity Group A/S Pharma Equity Group, et børsnoteret selskab på Nasdaq Copenhagen, er fuldt dedikeret til at fremme datterselskabet Reponex Pharmaceuticals A/S' lægemiddelkandidater. Med et urokkeligt fokus på Healthcare er Pharma E
Alternus Energy Reports Third Quarter 2023 Financial Results28.11.2023 14:30:00 CET | Press release
DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- International Renewable Independent Power Producer (IPP) Alternus Energy Group Plc (OSE: ALT) (the “Company” or “Alternus”) today announced unaudited U.S. GAAP financial results for the third quarter of 2023 under the US GAAP format. Q3 2023 Highlights Power production decreased by 5.4% YoY to 157 MWh due primarily to weather variances in Poland and the Netherlands.Revenue decreased by $1.9 million (15.3%) to $10.5 million compared to the same reporting period last year primarily because of lower electricity pricing in Poland and from lower irradiation levels due to seasonal weather conditions in Poland and the Netherlands.Gross profit increased by $0.5 million (6.4%) to $8.3 million resulting in gross margin of 79.0% as reduced revenues were offset by tightly controlled project operating costs.Selling and general expenses increased by $1 million (41%) YoY as the company grew personnel and infrastructure to drive development activities
Cellebrite Showcases Innovations in Digital Intelligence at Milipol 202328.11.2023 14:30:00 CET | Press release
Cellebrite demonstrates how agencies can increase productivity of digital investigations by making them smarter, more efficient and defensible TYSONS CORNER, Va. and PETAH TIKVA, Israel and PARIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, continued its commitment to accelerating justice around the globe with a leading presence at Milipol, the preeminent global law enforcement and homeland security event held November 14-17, 2023 in Paris. In addition to serving as one of the show’s sponsors, Cellebrite’s senior leadership, sales and service teams engaged with law enforcement professionals from more than 100 countries to discuss industry best practices and showcase recent innovations and emerging digital solutions. Highlights of Cellebrite’s show presence include: EMEA Senior Leadership convening with dozens of law enforcement professionals to discuss best practices and